Prostaglandin D2 receptor Antagonist - Pipeline Insight, 2022
This report can be delivered to the clients within 24 hours
DelveInsight’s, “DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview
Prostaglandin D2 receptor is a 395 amino acid, 43 kDa G-protein-coupled receptors. PGD2 is released following activation of the immune system, which can be either non-allergen- or allergen-dependent. Binding of PGD2 to the DP2 receptor on immune cells induces a myriad of pro-inflammatory downstream effects, which significantly contribute to the recruitment, activation and/or migration of TH2 cells, ILC2, and eosinophils. PGD2 produced by mast cells might provide an essential link between the early phase and late-phase allergic responses and such antagonism of PGD2 provides an attractive target for therapeutic intervention. Several selective, orally active, DP2 receptor antagonists are being developed for the treatment of allergic disorders.
Report Highlights
This segment of the DP1 Receptor (Prostaglandin D2 receptor) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs
Further product details are provided in the report……..
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs.
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in DP1 Receptor (Prostaglandin D2 receptor) Antagonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview
Prostaglandin D2 receptor is a 395 amino acid, 43 kDa G-protein-coupled receptors. PGD2 is released following activation of the immune system, which can be either non-allergen- or allergen-dependent. Binding of PGD2 to the DP2 receptor on immune cells induces a myriad of pro-inflammatory downstream effects, which significantly contribute to the recruitment, activation and/or migration of TH2 cells, ILC2, and eosinophils. PGD2 produced by mast cells might provide an essential link between the early phase and late-phase allergic responses and such antagonism of PGD2 provides an attractive target for therapeutic intervention. Several selective, orally active, DP2 receptor antagonists are being developed for the treatment of allergic disorders.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence DP1 Receptor (Prostaglandin D2 receptor) Antagonist R&D. The therapies under development are focused on novel approaches for DP1 Receptor (Prostaglandin D2 receptor) Antagonist.
This segment of the DP1 Receptor (Prostaglandin D2 receptor) Antagonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Emerging Drugs
- BGE-175: BioAge Labs
- SLS 008: Seelos Therapeutics
Further product details are provided in the report……..
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Therapeutic Assessment
This segment of the report provides insights about the different DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on DP1 Receptor (Prostaglandin D2 receptor) Antagonist
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs.
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Report Insights
- DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs?
- How many DP1 Receptor (Prostaglandin D2 receptor) Antagonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for DP1 Receptor (Prostaglandin D2 receptor) Antagonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DP1 Receptor (Prostaglandin D2 receptor) Antagonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for DP1 Receptor (Prostaglandin D2 receptor) Antagonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- CSPC ZhongQi Pharmaceutical Technology
- BioAge Labs
- Novartis
- Chiesi Farmaceutici
- Idorsia Pharmaceuticals
- Seelos Therapeutics
- Sunshine Lake Pharma
- CSPCHA-115
- Asapiprant
- Fevipiprant
- Timapiprant
- ACT-774312
- SLS 008
- Litapiprant
Introduction
Executive Summary
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
DP1 Receptor (Prostaglandin D2 receptor) Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• DP1 Receptor (Prostaglandin D2 receptor) Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Fevipiprant: Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
BGE-175: BioAge Labs
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
CSPCHA-115: CSPC ZhongQi Pharmaceutical Technology
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
SLS 008: Seelos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Products
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Unmet Needs
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Market Drivers and Barriers
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Future Perspectives and Conclusion
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Analyst Views
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies
Appendix
Executive Summary
DP1 Receptor (Prostaglandin D2 receptor) Antagonist: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
DP1 Receptor (Prostaglandin D2 receptor) Antagonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• DP1 Receptor (Prostaglandin D2 receptor) Antagonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Fevipiprant: Novartis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
BGE-175: BioAge Labs
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
CSPCHA-115: CSPC ZhongQi Pharmaceutical Technology
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
SLS 008: Seelos Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Products
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Unmet Needs
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Market Drivers and Barriers
DP1 Receptor (Prostaglandin D2 receptor) Antagonist- Future Perspectives and Conclusion
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Analyst Views
DP1 Receptor (Prostaglandin D2 receptor) Antagonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Prostaglandin D2 receptor Antagonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Prostaglandin D2 receptor Antagonist
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Prostaglandin D2 receptor Antagonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Prostaglandin D2 receptor Antagonist
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
